Should I buy Cidara Therapeutics Inc (CDTX)? · rev $1.3M
Cidara Therapeutics Inc (CDTX) is a biotechnology company listed on US.
This page is a buy-decision checklist for Cidara Therapeutics Inc (CDTX), not a recommendation. Use the cached numbers below to judge valuation, quality, and risk against your own horizon.
Latest reported CDTX revenue for 2024-12-31 was $1.3M. Net income was -$169.8M. Revenue was down 94.5% from 2023-12-31 to 2024-12-31. CDTX currently screens at market cap $6.96B.
On valuation: CDTX currently screens at market cap $6.96B. Compare that P/E and cap to the company's own history and to sector peers — a single ratio is not a buy or sell signal.
Read the latest CDTX 10-K/10-Q on the SEC page before you size a position. Filings beat a headline.
Not investment advice. If CDTX fits your process, the live tape and full model are on the CDTX stock and quote pages.
Not investment advice.